Nanoviricides Inc (NNVC) Stock Price, Quote & News

Company Profile

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gumm...

Industry: Biotechnology

Sector: Healthcare

Phone: 203 937 6137

Website: www.nanoviricides.com

Address:

1 Controls Drive, Shelton, United States

tomzprofit Feb. 4 at 7:47 AM

$NNVC CEO Anil Diwan talks about NV-387 being an "Empiric Therapy" like penicillin is now for bacteria infections. The drug has been shown to be effective in 90 to 95 % of all viruses. The global total market for antiviral drugs, not including vaccines is over $50 billion for 2025.

0 · Reply

STRAYNUT Feb. 3 at 11:19 PM

$NNVC Feb 02, 8:36 AM NanoViricides announces its NV-387 Phase II Mpox trial in the DRC has received ACOREP regulatory approval and completed the clinical trial application process, with first patient dosing expected to begin once site preparations are finished. FYI

0 · Reply

Love1010 Feb. 2 at 8:44 PM

$NNVC massive technical breakdown

0 · Reply

Love1010 Feb. 2 at 2:56 PM

$NNVC he's right, know what you own (and don't own)

0 · Reply

STRAYNUT Feb. 1 at 1:03 PM

$NNVC KNOW WHAT YOU OWN! https://www.nanoviricides.com/files/News%20PDFs/Broad-Spectrum%20NV-387%20To%20Enable%20Emperic%20Antiviral%20Treatment%20-%20A%20Revolutionary%20Prospect%20Reminisc.pdf

0 · Reply

STRAYNUT Jan. 30 at 11:55 PM

$NNVC Anil Diwan on Building Revolutionary Antiviral Therapieshttps://www.bing.com/videos/riverview/relatedvideo?qs=HS&pq=anil+diwan&sk=CSYN1&sc=8-10&pglt=393&q=anil+diwan+news&cvid=321bf7d1bc7c454c87600623ca43c0b1&gs_lcrp=EgRlZGdlKgcIABAAGPkHMgcIABAAGPkHMgYIARBFGDkyBggCEAAYQDIGCAMQABhAMgYIBBAAGEAyBggFEAAYQDIGCAYQABhAMgYIBxBFGEEyBggIEEUYPNIBCTE0NTU0ajBqMagCALACAA&DAF1=1%2c1&PC=HCTS&ru=%2fsearch%3fqs%3dHS%26pq%3danil%2bdiwan%26sk%3dCSYN1%26sc%3d8-10%26pglt%3d393%26q%3danil%2bdiwan%2bnews%26cvid%3d321bf7d1bc7c454c87600623ca43c0b1%26gs_lcrp%3dEgRlZGdlKgcIABAAGPkHMgcIABAAGPkHMgYIARBFGDkyBggCEAAYQDIGCAMQABhAMgYIBBAAGEAyBggFEAAYQDIGCAYQABhAMgYIBxBFGEEyBggIEEUYPNIBCTE0NTU0ajBqMagCALACAA%26FORM%3dANNTA1%26DAF1%3d1%26PC%3dHCTS%26daf1%3d1&mmscn=vwrc&mid=632E0D74B6B59F2638D6632E0D74B6B59F2638D6&FORM=WRVORC&ntb=1&msockid=4a50dba3fe3611f081a5ff153445c3fd

1 · Reply

CameoBrien Jan. 30 at 5:15 PM

$NNVC early but ready for the push

0 · Reply

CameoBrien Jan. 30 at 4:47 PM

$NNVC bids set

0 · Reply

Orphan_Drug_Guy Jan. 30 at 4:09 PM

$NNVC 👀 It's that time again!

1 · Reply

CameoBrien Jan. 30 at 1:50 PM

$NNVC @Love1010 Whats that babe?

1 · Reply

NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres

Jan 13, 2026, 8:30 AM EST - 21 days ago

NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2

Dec 1, 2025, 8:30 AM EST - 2 months ago

NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles

Nov 17, 2025, 8:30 AM EST - 2 months ago

NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position

Nov 14, 2025, 8:30 AM EST - 2 months ago

NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2

Nov 12, 2025, 5:01 PM EST - 2 months ago

NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

Nov 11, 2025, 8:30 AM EST - 3 months ago

NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

Nov 10, 2025, 8:30 AM EST - 3 months ago

NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo

Nov 5, 2025, 8:30 AM EST - 3 months ago

NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT

Nov 3, 2025, 8:30 AM EST - 3 months ago

NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd

Oct 29, 2025, 8:45 AM EDT - 3 months ago

Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive

Oct 27, 2025, 8:45 AM EDT - 3 months ago

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27

Oct 22, 2025, 8:45 AM EDT - 3 months ago

In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides

Oct 20, 2025, 8:45 AM EDT - 3 months ago

A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus

Oct 15, 2025, 8:45 AM EDT - 4 months ago

NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses

Sep 30, 2025, 8:45 AM EDT - 4 months ago

NanoViricides, Inc. Has Filed its Annual Report

Sep 11, 2025, 8:30 AM EDT - 5 months ago

RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

Sep 9, 2025, 8:30 AM EDT - 5 months ago

NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

Aug 18, 2025, 8:30 AM EDT - 6 months ago

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials

Jul 30, 2025, 8:30 AM EDT - 6 months ago

Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides

Jul 23, 2025, 8:30 AM EDT - 7 months ago

NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value

Jul 21, 2025, 6:30 AM EDT - 7 months ago

Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides

Jul 16, 2025, 8:30 AM EDT - 7 months ago

WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides

Jun 18, 2025, 6:30 AM EDT - 8 months ago

With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan

Jun 4, 2025, 6:55 AM EDT - 8 months ago

NanoViricides Measles Drug Development Animal Study is Imminent

May 28, 2025, 6:30 AM EDT - 9 months ago

NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025

May 22, 2025, 6:30 AM EDT - 9 months ago

The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan

May 14, 2025, 6:30 AM EDT - 9 months ago

Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution

May 5, 2025, 6:30 AM EDT - 9 months ago

NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC

Apr 29, 2025, 6:30 AM EDT - 10 months ago

Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It

Apr 14, 2025, 6:30 AM EDT - 10 months ago

Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak

Mar 11, 2025, 6:30 AM EDT - 11 months ago

NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company

Mar 4, 2025, 6:30 AM EST - 1 year ago

Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan

Feb 19, 2025, 6:30 AM EST - 1 year ago

NanoViricides, Inc. Has Filed its Quarterly Report

Feb 11, 2025, 6:30 AM EST - 1 year ago

NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape

Jan 29, 2025, 6:30 AM EST - 1 year ago

NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025

Jan 27, 2025, 6:30 AM EST - 1 year ago

NanoViricides Engages CRO for Phase II Clinical Trial

Jan 13, 2025, 6:30 AM EST - 1 year ago

NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025

Jan 8, 2025, 6:30 AM EST - 1 year ago

Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals

Dec 23, 2024, 6:30 AM EST - 1 year ago

NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape

Nov 15, 2024, 6:30 AM EST - 1 year ago

NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID

Nov 4, 2024, 12:00 AM EST - 1 year ago

NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am

Oct 22, 2024, 6:30 AM EDT - 1 year ago

NanoViricides President Dr. Diwan to Present at the PODD Conference

Oct 15, 2024, 6:30 AM EDT - 1 year ago

NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology

Oct 8, 2024, 6:30 AM EDT - 1 year ago

NanoViricides to Present at the Global AMR Summit 2024 Tomorrow

Sep 30, 2024, 6:30 AM EDT - 1 year ago

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID

Sep 26, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs

Aug 26, 2024, 7:30 AM EDT - 1 year ago

MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX

Aug 19, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 - A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections

Aug 8, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics

tomzprofit Feb. 4 at 7:47 AM

0 · Reply

STRAYNUT Feb. 3 at 11:19 PM

0 · Reply

Love1010 Feb. 2 at 8:44 PM

$NNVC massive technical breakdown

0 · Reply

Love1010 Feb. 2 at 2:56 PM

$NNVC he's right, know what you own (and don't own)

0 · Reply

STRAYNUT Feb. 1 at 1:03 PM

$NNVC KNOW WHAT YOU OWN! https://www.nanoviricides.com/files/News%20PDFs/Broad-Spectrum%20NV-387%20To%20Enable%20Emperic%20Antiviral%20Treatment%20-%20A%20Revolutionary%20Prospect%20Reminisc.pdf

0 · Reply

STRAYNUT Jan. 30 at 11:55 PM

1 · Reply

CameoBrien Jan. 30 at 5:15 PM

$NNVC early but ready for the push

0 · Reply

CameoBrien Jan. 30 at 4:47 PM

$NNVC bids set

0 · Reply

Orphan_Drug_Guy Jan. 30 at 4:09 PM

$NNVC 👀 It's that time again!

1 · Reply

CameoBrien Jan. 30 at 1:50 PM

$NNVC @Love1010 Whats that babe?

1 · Reply

Love1010 Jan. 30 at 1:46 PM

$NNVC ask yourself about @NoHandOutz and @CameoBrien who never posted here but come out all at once to pump the stock. Clearly this this manipulation because the know the shorts are in control and want in on the game. Complete rubbish just like this stock.

0 · Reply

CameoBrien Jan. 30 at 1:15 PM

$NNVC room to run

0 · Reply

CameoBrien Jan. 30 at 12:36 PM

$NNVC ready

0 · Reply

NoHandOutz Jan. 30 at 11:32 AM

$NNVC playtime is over shorts

0 · Reply

Love1010 Jan. 29 at 9:53 PM

$NNVC will it become an infinite penny stock?

0 · Reply

Love1010 Jan. 28 at 7:01 PM

$NNVC how many hours until Diwan puts out his bogus Nipah Virus PR?

0 · Reply

Love1010 Jan. 28 at 6:14 PM

$NNVC crime of the century

0 · Reply

CameoBrien Jan. 28 at 1:12 PM

$NNVC 👀

0 · Reply

BillionerOfKing Jan. 28 at 12:59 AM

$NNVC Current Stock Price: $1.09 Contracts to trade: $2.5 NNVC Feb 20 2026 Call Entry: $0.05 Exit: $0.08 ROI: 85% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

STRAYNUT Jan. 28 at 12:16 AM

$NNVC Short Interest (01/15/26) Shares Sold Short 657,631 Change from Last 43.45% Percent of Float 3.14% https://www.wsj.com/market-data/quotes/NNVC

0 · Reply

Love1010 Jan. 27 at 6:56 PM

$NNVC once again when people come out with the latest virus outbreak they somehow think this company which has no product, no proof, and no pot to piss in will somehow be the saving grace, they leading you to the ledge of money losses and heavy losers!

0 · Reply

STRAYNUT Jan. 26 at 5:07 PM

$NNVC India battles deadly Nipah virus outbreak: what to know https://www.msn.com/en-us/health/other/india-battles-deadly-nipah-virus-outbreak-what-to-know/ar-AA1V0LJF?ocid=BingNewsSerp

0 · Reply

Market Cap	20.81M
Revenue (ttm)	0.00
Net Income (ttm)	-9.47M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	175,800
Avg Vol	302,824
Day's Range	N/A - N/A
Shares Out	21.57M
Stochastic %K	6%
Beta	1.23
Analysts	Strong Sell
Price Target	$6.50